<DOC>
	<DOCNO>NCT02596451</DOCNO>
	<brief_summary>This Randomized , Double-Blind , Placebo-Controlled , Parallel-Design , Multiple-Site Clinical Study Evaluate Therapeutic Equivalence Diclofenac Sodium Gel , 1 % ( Glenmark Pharmaceuticals Ltd ) Voltaren® Gel ( Diclofenac Sodium topical gel ) 1 % ( Novartis Consumer Health , Inc ) Patients Osteoarthritis ( OA ) Knee</brief_summary>
	<brief_title>To Study Generic Diclofenac Sodium Topical Gel 1 % Treatment Osteoarthritis Knee ( Degenerative Joint Disease Presented Joint Pain , Stiffness , Swelling Restricted Motion ) .</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>1 . Healthy male nonpregnant female age ≥ 35 year clinical diagnosis OA knee accord American College Rheumatology ( ACR ) criterion . 2 . OA Symptoms least 6 month prior screen . 3 . Baseline Western Ontario McMaster Osteoarthritis ( WOMAC ) pain subscale &gt; 9 20 point scale target knee immediately prior randomization . 1 . History OA pain contralateral knee require medication within 1 year prior screen . 2 . History secondary OA , rheumatoid arthritis , chronic inflammatory disease ( e.g. , colitis ) fibromyalgia . 3 . History gastrointestinal bleeding peptic ulcer disease . 4 . Known allergy aspirin nonsteroidal antiinflammatory drug ( NSAID ) . 5 . Use anticoagulant , ACEinhibitors , cyclosporine , diuretic , lithium , methotrexate prior 30 day screen . 6 . Concomitant use systemic corticosteroid , topical corticosteroid , immunosuppressive drug use prior 30 day screen .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>